Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

NCT02307240 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-Negative Breast Cancer
High-grade Serous Ovarian Cancer
Solid Tumors
NUT Midline Carcinoma

Interventions

DRUG: CUDC-907

Sponsor

Curis, Inc.